SDZNY vs. STVN: Which Stock Offers Better Value?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy STVN?
Source: NASDAQ.COM
Stock Comparison: Sandoz Group AG Sponsored ADR (SDZNY) has a Zacks Rank of #2 (Buy) indicating a strong earnings outlook, while Stevanato Group (STVN) has a Zacks Rank of #3 (Hold), suggesting a weaker position.
Valuation Metrics: SDZNY shows a forward P/E ratio of 22.38 and a PEG ratio of 1.20, indicating better value compared to STVN's forward P/E of 34.66 and PEG ratio of 2.03.
Value Grades: Based on various valuation metrics, SDZNY holds a Value grade of B, while STVN has a Value grade of C, further supporting SDZNY as the superior value option.
Investment Recommendations: Zacks Investment Research highlights SDZNY as a strong investment opportunity, alongside other top stock recommendations with potential for significant returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STVN
Wall Street analysts forecast STVN stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 16.300
Low
24.00
Averages
27.00
High
30.00
Current: 16.300
Low
24.00
Averages
27.00
High
30.00
About STVN
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Stevanato Group to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Stevanato Group will issue its financial results for Q4 and FY 2025 on March 4, 2026, at 6:30 a.m. (ET), reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call and webcast at 8:30 a.m. (ET) on the same day, where management will refer to a slide presentation to enhance investor understanding of the financial results.
- Pre-registration Convenience: Participants can pre-register to receive a conference passcode and unique PIN for immediate access to the call, demonstrating the company's focus on improving investor experience.
- Webcast Archive: The webcast will be archived for three months on the company's Investor Relations website, ensuring that investors who cannot attend live can still access critical information, further enhancing information accessibility.
See More
Stevanato Group to Release Q4 and FY 2025 Financial Results
- Financial Results Announcement: Stevanato Group will issue its financial results for Q4 and FY 2025 on March 4, 2026, at 6:30 a.m. (ET), highlighting its market performance in the pharmaceutical and biotechnology sectors.
- Conference Call Details: The company will host a conference call and webcast at 8:30 a.m. (ET) on the same day to discuss financial results, with management providing a slide presentation to enhance investor understanding of the company's performance.
- Pre-registration Convenience: Participants can pre-register to receive a conference passcode and unique PIN for quick access to the call, encouraging greater investor participation and enhancing the overall experience.
- Webcast Replay Availability: The webcast will be archived for three months on the company's Investor Relations website, ensuring that investors who cannot attend live can access the information later, thereby increasing transparency and information sharing.
See More
S&P 500 Index Edges Up as Tech Stocks Rally
- Tech Stock Rally: The S&P 500 Index rose by 0.03% driven by a rebound in the Magnificent Seven tech stocks, indicating a recovery in market confidence despite ongoing uncertainties.
- Consumer Confidence Boost: The University of Michigan's consumer sentiment index was revised up to 56.4, a five-month high, exceeding expectations of 54.0, suggesting increased consumer confidence that could stimulate spending.
- Easing Inflation Expectations: The one-year inflation expectations were revised down from 4.2% to 4.0%, reflecting a reduction in market concerns about future inflation, which may support stock performance.
- Oil Price Surge: WTI crude oil prices jumped over 2% to a one-week high as President Trump reiterated military threats against Iran, boosting energy stocks and highlighting the impact of geopolitical risks on the market.
See More
S&P 500 Futures Rise in Pre-Market Session; Venture Global and Karman Holdings Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Venture Global Inc. Performance: Venture Global Inc. (VG) saw a 9.9% increase in pre-market trading.
- Karman Holdings Inc. Performance: Karman Holdings Inc. (KRMN) experienced a 9.5% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Growing Market Demand: According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, driving the need for large-volume subcutaneous drug delivery solutions, prompting Datwyler's collaboration with LTS and Stevanato to address market shifts.
- Patient Self-Administration Convenience: A Mayo Clinic study found that 73% of participants preferred in-home self-administration, highlighting the urgent demand for convenient patient-centric healthcare solutions, with Datwyler's NeoFlex™ plungers enhancing the reliability and safety of large-volume injection systems.
- Technological Innovation Showcase: The three companies will jointly present their platform solution at Pharmapack on January 21-22, 2026, aiming to optimize the development of pre-verified container closure systems, advancing technology for large-volume drug self-administration.
- Accelerated Market Access: Through collaboration, the companies will offer a pre-verified ecosystem to expedite market access, meeting stringent safety and efficacy requirements for self-administered therapies of up to 20 mL, further solidifying their market leadership in drug delivery solutions.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Market Demand Response: Datwyler's collaboration with LTS Device Technologies and Stevanato Group introduces large-volume subcutaneous drug delivery solutions, addressing the needs of 73% of patients who prefer in-home self-administration, thus facilitating a shift towards personalized healthcare at home.
- Technology Innovation Showcase: The three companies will unveil their pre-verified large-volume drug delivery platform at Pharmapack on January 21-22, 2026, aiming to accelerate market access and enhance patient medication experiences.
- Product Functionality Enhancement: Datwyler's NeoFlex™ plungers support drug delivery volumes of up to 20mL, overcoming the limitations of traditional low-volume delivery while ensuring safety and therapeutic efficacy, catering to the rapid growth of the biologics market.
- Industry Outlook: The U.S. biologics market is projected to reach $483 billion by 2034, and Datwyler's collaboration will provide innovative solutions for pharmaceutical companies, helping them maintain a competitive edge in a challenging market.
See More
Stevanato Group to Release Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Stevanato Group will issue its financial results for Q4 and FY 2025 on March 4, 2026, at 6:30 a.m. (ET), reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call and webcast at 8:30 a.m. (ET) on the same day, where management will refer to a slide presentation to enhance investor understanding of the financial results.
- Pre-registration Convenience: Participants can pre-register to receive a conference passcode and unique PIN for immediate access to the call, demonstrating the company's focus on improving investor experience.
- Webcast Archive: The webcast will be archived for three months on the company's Investor Relations website, ensuring that investors who cannot attend live can still access critical information, further enhancing information accessibility.
See More
Stevanato Group to Release Q4 and FY 2025 Financial Results
- Financial Results Announcement: Stevanato Group will issue its financial results for Q4 and FY 2025 on March 4, 2026, at 6:30 a.m. (ET), highlighting its market performance in the pharmaceutical and biotechnology sectors.
- Conference Call Details: The company will host a conference call and webcast at 8:30 a.m. (ET) on the same day to discuss financial results, with management providing a slide presentation to enhance investor understanding of the company's performance.
- Pre-registration Convenience: Participants can pre-register to receive a conference passcode and unique PIN for quick access to the call, encouraging greater investor participation and enhancing the overall experience.
- Webcast Replay Availability: The webcast will be archived for three months on the company's Investor Relations website, ensuring that investors who cannot attend live can access the information later, thereby increasing transparency and information sharing.
See More
S&P 500 Index Edges Up as Tech Stocks Rally
- Tech Stock Rally: The S&P 500 Index rose by 0.03% driven by a rebound in the Magnificent Seven tech stocks, indicating a recovery in market confidence despite ongoing uncertainties.
- Consumer Confidence Boost: The University of Michigan's consumer sentiment index was revised up to 56.4, a five-month high, exceeding expectations of 54.0, suggesting increased consumer confidence that could stimulate spending.
- Easing Inflation Expectations: The one-year inflation expectations were revised down from 4.2% to 4.0%, reflecting a reduction in market concerns about future inflation, which may support stock performance.
- Oil Price Surge: WTI crude oil prices jumped over 2% to a one-week high as President Trump reiterated military threats against Iran, boosting energy stocks and highlighting the impact of geopolitical risks on the market.
See More
S&P 500 Futures Rise in Pre-Market Session; Venture Global and Karman Holdings Take the Lead
- Market Opening: U.S. stock markets are set to open in two hours.
- Venture Global Inc. Performance: Venture Global Inc. (VG) saw a 9.9% increase in pre-market trading.
- Karman Holdings Inc. Performance: Karman Holdings Inc. (KRMN) experienced a 9.5% rise in pre-market trading.
- Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Growing Market Demand: According to Precedence Research, the U.S. biologics market is projected to reach $483 billion by 2034, driving the need for large-volume subcutaneous drug delivery solutions, prompting Datwyler's collaboration with LTS and Stevanato to address market shifts.
- Patient Self-Administration Convenience: A Mayo Clinic study found that 73% of participants preferred in-home self-administration, highlighting the urgent demand for convenient patient-centric healthcare solutions, with Datwyler's NeoFlex™ plungers enhancing the reliability and safety of large-volume injection systems.
- Technological Innovation Showcase: The three companies will jointly present their platform solution at Pharmapack on January 21-22, 2026, aiming to optimize the development of pre-verified container closure systems, advancing technology for large-volume drug self-administration.
- Accelerated Market Access: Through collaboration, the companies will offer a pre-verified ecosystem to expedite market access, meeting stringent safety and efficacy requirements for self-administered therapies of up to 20 mL, further solidifying their market leadership in drug delivery solutions.
See More
Datwyler Collaborates with LTS and Stevanato to Launch Large-Volume Drug Delivery Solutions
- Market Demand Response: Datwyler's collaboration with LTS Device Technologies and Stevanato Group introduces large-volume subcutaneous drug delivery solutions, addressing the needs of 73% of patients who prefer in-home self-administration, thus facilitating a shift towards personalized healthcare at home.
- Technology Innovation Showcase: The three companies will unveil their pre-verified large-volume drug delivery platform at Pharmapack on January 21-22, 2026, aiming to accelerate market access and enhance patient medication experiences.
- Product Functionality Enhancement: Datwyler's NeoFlex™ plungers support drug delivery volumes of up to 20mL, overcoming the limitations of traditional low-volume delivery while ensuring safety and therapeutic efficacy, catering to the rapid growth of the biologics market.
- Industry Outlook: The U.S. biologics market is projected to reach $483 billion by 2034, and Datwyler's collaboration will provide innovative solutions for pharmaceutical companies, helping them maintain a competitive edge in a challenging market.
See More
